JP5271188B2 - 炎症治療薬の調製のためのミゾラスチンの使用 - Google Patents
炎症治療薬の調製のためのミゾラスチンの使用 Download PDFInfo
- Publication number
- JP5271188B2 JP5271188B2 JP2009179561A JP2009179561A JP5271188B2 JP 5271188 B2 JP5271188 B2 JP 5271188B2 JP 2009179561 A JP2009179561 A JP 2009179561A JP 2009179561 A JP2009179561 A JP 2009179561A JP 5271188 B2 JP5271188 B2 JP 5271188B2
- Authority
- JP
- Japan
- Prior art keywords
- mizolastine
- inflammatory
- pct
- preparation
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
ミゾラスチンの「インビトロ」活性は、ラットおよびヒトにおける5−LOにて研究した。
ラット白血病性好塩基性細胞(RBL−1)試料から得た5−LOを用いて、R.W. Egan および P.H. Gale により J. Biol. Chem., 260, 1154-1159, 1985 に開示された方法に従って試験を行った。ミゾラスチンを該酵素と一緒に室温で5分間インキュベートし、リノール酸を添加して反応を開始する。室温で8分間インキュベートした後、水酸化ナトリウムの添加により反応を停止し、234nmで吸光度を測定し、5−HETEの量を測定した。
阻害濃度(IC50)として表したミゾラスチン活性は、4.6μMである。
市販のHL60細胞から単離した5−LOにてミゾラスチンを試験した。アラキドン酸(0.4μM)および5−LOの存在下、ミゾラスチンを室温で10分間インキュベートする。参照生成物としてノルジヒドログアイアレチン酸の存在下での実験を同時に行う。形成した5−HETEの量をRIA(Coffrey et al., J. Biol. Chem., 267-270, 1992)により測定する。
阻害濃度(IC50)として表したミゾラスチン活性は、16μMである。
ミゾラスチンのインビボ活性は、ラットの肢炎症モデルおよびラットの大腸炎モデルにおいて研究した。
a)AAの注射による炎症
AAの使用濃度が0.3%(v/v)である以外は Di Martino et al.(Agents and actions, 21, 303-305, 1987)の方法に従って、AAの注射によりラットの肢に炎症性水腫を誘発させ、評価する。
AA注射の2時間前にミゾラスチンを経口投与する。使用時に緩衝液(0.1ml;0.2M炭酸塩;pH=11.2)で調製したAA溶液をラットの右後肢の足底部に注射する。
1、2、3および4時間後、炎症反応の容量をプレスチモグラフィにより測定する。
ミゾラスチンは、投与量0.3mg/kgで、対照と比較して、4時間後、誘発される炎症の55%の持続性阻害を与える。
Morris et al.(Gastroenterology, 96, 795-803, 1989)により開示された方法に従って、トリニトロベンゼンスルホン酸(TNBS)により誘発されたラットの直腸結腸炎モデルにおいて、ミゾラスチンを研究した。
TNBS(50%エタノール中40mg/kg)の結腸遠位部への点滴注入の1時間前および1日後にミゾラスチンを経口投与する(3mg/kg)。3日後、好中球の浸潤の尺度として、損傷の肉眼的指標、水腫/肥大(組織の重量)およびミエロペルオキシダーゼ活性の測定を行う。ミゾラスチンは、3mg/kgで、各々、67%、57%および66%の損傷、水腫/肥大(組織の重量)およびミエロペルオキシダーゼ活性の有意な減少を与える。
Claims (1)
- ミゾラスチンまたはその塩を含む、慢性関節リウマチ、嚢胞性線維症、炎症性腸症候群、胃炎、クローン病、回結腸炎、全腸炎、出血性直腸結腸炎または炎症性大腸炎の治療のための医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9704801A FR2762214B1 (fr) | 1997-04-17 | 1997-04-17 | Utilisation de la mizolastine pour la preparation d'un medicament destine au traitement de l'inflammation |
FR97/04801 | 1997-04-17 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54514798A Division JP2001523242A (ja) | 1997-04-17 | 1998-04-16 | 炎症治療薬の調製のためのミゾラスチンの使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009292827A JP2009292827A (ja) | 2009-12-17 |
JP5271188B2 true JP5271188B2 (ja) | 2013-08-21 |
Family
ID=9506075
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54514798A Withdrawn JP2001523242A (ja) | 1997-04-17 | 1998-04-16 | 炎症治療薬の調製のためのミゾラスチンの使用 |
JP2009179561A Expired - Fee Related JP5271188B2 (ja) | 1997-04-17 | 2009-07-31 | 炎症治療薬の調製のためのミゾラスチンの使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54514798A Withdrawn JP2001523242A (ja) | 1997-04-17 | 1998-04-16 | 炎症治療薬の調製のためのミゾラスチンの使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US6140335A (ja) |
EP (1) | EP1007047B1 (ja) |
JP (2) | JP2001523242A (ja) |
AT (1) | ATE312611T1 (ja) |
AU (1) | AU7436098A (ja) |
DE (1) | DE69832796T2 (ja) |
DK (1) | DK1007047T3 (ja) |
ES (1) | ES2253816T3 (ja) |
FR (1) | FR2762214B1 (ja) |
WO (1) | WO1998047511A1 (ja) |
ZA (1) | ZA983211B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0958820A1 (en) * | 1998-05-19 | 1999-11-24 | Sanofi-Synthelabo | Use of an imidazol derivative for the manufacture of a medicament for treating auto-immunodiseases |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2587029B1 (fr) * | 1985-09-11 | 1987-10-30 | Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
-
1997
- 1997-04-17 FR FR9704801A patent/FR2762214B1/fr not_active Expired - Fee Related
-
1998
- 1998-04-16 ZA ZA983211A patent/ZA983211B/xx unknown
- 1998-04-16 AU AU74360/98A patent/AU7436098A/en not_active Abandoned
- 1998-04-16 EP EP98921544A patent/EP1007047B1/fr not_active Expired - Lifetime
- 1998-04-16 DK DK98921544T patent/DK1007047T3/da active
- 1998-04-16 DE DE69832796T patent/DE69832796T2/de not_active Expired - Lifetime
- 1998-04-16 JP JP54514798A patent/JP2001523242A/ja not_active Withdrawn
- 1998-04-16 US US09/403,005 patent/US6140335A/en not_active Expired - Lifetime
- 1998-04-16 WO PCT/FR1998/000765 patent/WO1998047511A1/fr active IP Right Grant
- 1998-04-16 AT AT98921544T patent/ATE312611T1/de active
- 1998-04-16 ES ES98921544T patent/ES2253816T3/es not_active Expired - Lifetime
-
2009
- 2009-07-31 JP JP2009179561A patent/JP5271188B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2001523242A (ja) | 2001-11-20 |
DE69832796D1 (de) | 2006-01-19 |
FR2762214B1 (fr) | 2000-10-06 |
US6140335A (en) | 2000-10-31 |
EP1007047A1 (fr) | 2000-06-14 |
ES2253816T3 (es) | 2006-06-01 |
JP2009292827A (ja) | 2009-12-17 |
FR2762214A1 (fr) | 1998-10-23 |
ATE312611T1 (de) | 2005-12-15 |
DE69832796T2 (de) | 2006-08-31 |
EP1007047B1 (fr) | 2005-12-14 |
WO1998047511A1 (fr) | 1998-10-29 |
DK1007047T3 (da) | 2006-05-08 |
AU7436098A (en) | 1998-11-13 |
ZA983211B (en) | 1998-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Behr-Roussel et al. | Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis | |
US20210023043A1 (en) | Methods of Treating Hyperalgesia | |
AU2005231490B2 (en) | Methods of treatment using eszopiclone | |
KR102293847B1 (ko) | 근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도 | |
JP2021073258A (ja) | トラジピタントによる治療方法 | |
TW200418460A (en) | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | |
JP2017014224A (ja) | 帯状疱疹関連痛の急性期疼痛の予防又は治療剤 | |
EP3368040B1 (en) | Methods and compositions for recovery from stroke | |
JP6959371B2 (ja) | 純粋な5−ht6受容体アンタゴニストの新たな使用 | |
WO1997021439A1 (fr) | Medicament destine au traitement des troubles obsessifs compulsifs, de l'apnee du sommeil, des dysfonctions sexuelles, de l'emese et du mal des transports | |
EA015483B1 (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ | |
JP5271188B2 (ja) | 炎症治療薬の調製のためのミゾラスチンの使用 | |
EA038087B1 (ru) | Трехкомпонентная фармацевтическая комбинация чистых антагонистов 5-ht6 рецепторов, ингибиторов ацетилхолинэстеразы и антагониста nmda рецептора, применение указанной комбинации и содержащей ее фармацевтической композиции в лечении когнитивных расстройств и способ такого лечения | |
JPH05506441A (ja) | 加齢関連記憶障害およびその他の認識障害の治療のための化合物 | |
JP2019524682A (ja) | 抗うつ作用の速い発現のためのボルチオキセチン投与計画 | |
RU2774970C2 (ru) | Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства | |
JPWO2004082683A1 (ja) | 慢性皮膚疾患の治療および/または予防剤 | |
JP2023510082A (ja) | 認知症患者における行動・心理症状を治療するための方法 | |
EA040280B1 (ru) | КОНДЕНСИРОВАННЫЕ БИЦИКЛИЧЕСКИЕ СТИМУЛЯТОРЫ sGC | |
KR102128810B1 (ko) | 요산 또는 통풍 질환의 예방 또는 치료 | |
TWI298022B (en) | Pharmaceutical compositions for the prophylaxis or treatment of atrial remodeling or atrial fibrillation | |
AU2011202540B2 (en) | Methods of treatment using eszopiclone | |
TW201033198A (en) | Pharmacokinetically-based dosing regimens of a thrombin receptor antagonist | |
BRPI0615357A2 (pt) | combinação de um agente hipnótico e r (+)-alfa-(2,3-dimetóxi-fenil)-1-[2-(4-fluorofenil)etil]-4-pi peridinometanol e aplicação terapêutica do mesmo | |
BRPI0611719A2 (pt) | uso farmacÊutico de uma 1-(3-clorofenil)-3-alquilpiperazina, e, composiÇço farmacÊutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120815 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121016 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130215 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130227 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130423 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130510 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |